Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a control toothpaste formulation containing 0.76% sodium monofluorophosphate (SMFP), developed by GSK for use as a negative control in clinical trials evaluating treatments for dentinal hypersensitivity. Sodium monofluorophosphate is a source of fluoride used primarily for caries prevention; in the context of sensitivity trials, it serves as a standard non-desensitizing fluoride control to compare against active desensitizing agents like stannous fluoride or potassium nitrate. It works by releasing fluoride ions to promote remineralization of tooth enamel but lacks the specific tubule-occluding or nerve-desensitizing properties of the test agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium monofluorophosphate 0.76% toothpaste.